GlassScriptPhysician profile
Monica Tran
NPI 1184856155
$2,122.93
in general payments reported to CMS, 2019-2025
22 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2021: $45.18 · 2022: $142 · 2023: $546 · 2024: $548 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $418.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $191.32 | 2022-2025 | Vraylar, Ubrelvy |
| Exact Sciences Corporation | $189.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $187.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $168.64 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $135.82 | 2023-2025 | |
| Irhythm Technologies, INC. | $108.58 | 2019 | |
| Abbott Laboratories | $98.82 | 2021-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $97.29 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $93.94 | 2019-2025 | Bexsero, Shingrix, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.77 | 2022-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $72.65 | 2022-2024 | Quviviq |
| Amgen INC. | $66.15 | 2025 | Repatha, Otezla |
| Astellas Pharma US INC | $59.02 | 2023-2025 | Veozah |
| Merz Pharmaceuticals, LLC | $39.33 | 2024 | Xeomin |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $24.26 | 2023 | Tymlos |
| Neos Therapeutics, LP | $18.43 | 2023 | Adzenys Xr-Odt |
| Alk-Abello, INC | $18.22 | 2025 | Grastek, Ragwitek, Odactra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.36 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $15.17 | 2025 | Gardasil 9, Capvaxive |
| Currax Pharmaceuticals LLC | $14.95 | 2023 | Contrave |
| Medtronic, INC. | $14.76 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.